Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Semaglutide is a GLP-1 agonist that works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a glucagon-like ...

Microdosing GLP-1 has been touted for everything for weight management to perimenopause symptoms. But is it all it’s cracked ...